SCHEMBL4076975

SCHEMBL4076975

COc1nccc(OC(F)F)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 5/20 0.38
ATP4B P51164 5/20 0.38
ATP1A1 P05023 3/20 0.38
ATP1B1 P05026 3/20 0.38
ATP1A3 P13637 3/20 0.38
ATP1B2 P14415 3/20 0.38
ATP1A2 P50993 3/20 0.38
ATP1B3 P54709 3/20 0.38
FXYD2 P54710 3/20 0.38
ATP1A4 Q13733 3/20 0.38
GRIN1 Q05586 3/20 0.35
GRIN2B Q13224 3/20 0.35
RXRA P19793 2/20 0.35
TRPV4 Q9HBA0 1/20 0.35
ALDH1A1 P00352 1/20 0.35
DRD1 P21728 4/20 0.34
GAA P10253 1/20 0.33
BACE1 P56817 1/20 0.33
KCNN4 O15554 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208670 0.89 TRPV4 (0.40) ATP4AATP4BATP1A1ATP1B1ATP1A3
SCHEMBL4079859 0.86 ATP4A (0.40) ATP4AATP4BATP1A1ATP1B1ATP1A3
SCHEMBL4069883 0.83 HPGD (0.49) ATP4AATP4BATP1A1ATP1B1ATP1A3
SCHEMBL4076971 0.81 GRIN1 (0.34) ATP4AATP4BATP1A1ATP1B1ATP1A3
SCHEMBL4074890 0.81 ALDH1A1 (0.44) ALDH1A1DRD1GAAHPGDSMN1; SMN2
SCHEMBL188338 0.76 GRIN1 (0.48) GRIN1GRIN2BRXRATRPV4DRD1
SCHEMBL4082143 0.75 RUNX1 (0.35) ALDH1A1DRD1GAAHPGDSMN1; SMN2
SCHEMBL24344996 0.74 HCRTR1 (0.39) ALDH1A1DRD1HPGDSMN1; SMN2
SCHEMBL4079858 0.74 TRPV4 (0.37) ATP4AATP4BATP1A1ATP1B1ATP1A3
SCHEMBL27476345 0.74 HPGD (0.35) ALDH1A1GAAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572918-B2 Prepared in high yield and high purity without the need for isolation of intermediates and chromatographic purification; useful as muscarinic receptor antagonists; 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl)-hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine THERAVANCE, INC. (US) 2009-08-11 US disclosed
US-20080091034-A1 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. 2008-04-17 US disclosed
US-7285564-B2 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. (US) 2007-10-23 US disclosed
EP-1556372-B1 SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS THERAVANCE INC (US) 2007-05-30 EP disclosed
US-20060094878-A1 Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094878-A1 Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds CHRM4, CHRM3, CHRM1 ATP4A 2517/4885ATP4B 1904/4885ATP1A1 3539/4885
US-20080091034-A1 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds CHRM5, CHRM1, CHRM3 ATP4A 1516/4885ATP4B 1578/4885ATP1A1 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.